First Light Asset Management Reduces Stake in AnaptysBio

Biotechnology company sees institutional investor sell off over 2.5 million shares

Mar. 16, 2026 at 10:05am

Got story updates? Submit your updates here. ›

First Light Asset Management LLC has reduced its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 72% during the third quarter, according to a recent SEC filing. The fund now owns 990,161 shares of the biotechnology company's stock, down from 3.5 million shares previously held.

Why it matters

This significant reduction in First Light's stake in AnaptysBio could signal a shift in investor sentiment around the company and its pipeline of immunology and inflammation therapies. Institutional investors closely watch each other's moves, so this sell-off may influence how other funds view the stock going forward.

The details

According to the filing, First Light Asset Management sold 2,549,432 shares of AnaptysBio during the third quarter. The fund now owns approximately 3.58% of the company's outstanding shares, down from a previous 12.7% stake. AnaptysBio is developing several clinical-stage antibody programs to treat various immune-mediated conditions.

  • First Light Asset Management reduced its AnaptysBio position during the third quarter of 2026.

The players

First Light Asset Management LLC

An investment management firm that has reduced its stake in biotechnology company AnaptysBio.

AnaptysBio, Inc.

A clinical-stage biotechnology company focused on developing therapeutic antibody products for immunology and inflammation.

Got photos? Submit your photos here. ›

The takeaway

This significant sell-off by a major institutional investor in AnaptysBio could signal broader concerns about the company's prospects or the overall biotech market. Investors will be closely watching to see if other funds follow suit or if First Light's move is an outlier.